![BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older | Business Wire BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older | Business Wire](https://mms.businesswire.com/media/20210723005083/en/484259/22/Logo.jpg)
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older | Business Wire
![Dosing and Administration | BYDUREON BCise® (exenatide extended-release) injectable suspension 2 mg | For HCPs Dosing and Administration | BYDUREON BCise® (exenatide extended-release) injectable suspension 2 mg | For HCPs](https://www.bydureonhcp.com/content/dam/physician-services/us/486-hcp-bcise/release-4/unlock.png)
Dosing and Administration | BYDUREON BCise® (exenatide extended-release) injectable suspension 2 mg | For HCPs
![Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/bydureon-bcise3.gif)